RemeGen Co. Ltd. Class A
688331
Rank in Stocks
#2477
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Share Price
$14.07
Last synced: 2026-10-19
Market Cap
$7.88B
Change (1 day)
-2.90%
Change (1 year)
6.01%
Country
CN
Trade RemeGen Co. Ltd. Class A (688331)
Category
Healthcare
Number of shares outstanding for RemeGen Co. Ltd. Class A (688331)
Number of shares outstanding as of June 2026: 560.16M
According to RemeGen Co. Ltd. Class A latest financial reports and stock price the company's current number of shares outstanding is 560.16M. At the end of December 2023 the company had 539.72M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for RemeGen Co. Ltd. Class A (688331) from 2018 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 560.16M | 4.24% |
| 2024 | 537.39M | -0.43% |
| 2023 | 539.72M | 1.81% |
| 2022 | 530.12M | 8.76% |
| 2021 | 487.44M | 19.43% |
| 2020 | 408.15M | -14.68% |
| 2019 | 478.36M | 0.00% |
| 2018 | 478.36M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -54.67% |
US
|
|
| 396.00M | -29.31% |
US
|
|
| 478.91M | -14.51% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -88.90% |
NL
|
